These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38381215)

  • 21. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
    Wang S; Sun L
    Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
    Li L; Yang W; Pan Y; Ye R; Wang Y; Li S; Jiang H; Zhang Q; Wang X; Yan J
    Leuk Lymphoma; 2024 Jul; 65(7):895-910. PubMed ID: 38497543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
    Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
    Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
    Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y; Zhang X
    Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
    Cao HY; Li L; Xue SL; Dai HP
    Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.
    Li Q; Huang J; Ou Y; Li Y; Wu Y
    Immunotherapy; 2019 Mar; 11(4):265-272. PubMed ID: 30606076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report.
    Yang D; Zhang WP; Yang JM; He MX; Cheng C; Chen J
    Medicine (Baltimore); 2018 Dec; 97(49):e13093. PubMed ID: 30544372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
    Yousefi Z; Sharifzadeh S; Zare F; Eskandari N
    Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
    Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.
    Zhang X; Su Q; Zhang Y; Rong R; Chen S; He L; Zhuang W; Li B
    Ann Hematol; 2024 Aug; 103(8):2905-2915. PubMed ID: 38424303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
    Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY
    Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathway.
    Hu K; Li B; Ma R; Yi H; Xu Z; Peng Y; Yu D; Wu H; Cheng T; Lu Y; Zhang Y; Wei R; Yang G; Wu X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):575-583. PubMed ID: 33821934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.